BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11681418)

  • 1. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome.
    Miyamoto N; Sugita K; Goi K; Inukai T; Lijima K; Tezuka T; Kojika S; Nakamura M; Kagami K; Nakazawa S
    Leukemia; 2001 Nov; 15(11):1758-68. PubMed ID: 11681418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome.
    Iijima K; Sugita K; Inukai T; Goi K; Tezuka T; Uno K; Sato H; Kagami K; Nakazawa S
    Leukemia; 2000 Sep; 14(9):1598-605. PubMed ID: 10995006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
    Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
    Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase.
    Frasor J; Barkai U; Zhong L; Fazleabas AT; Gibori G
    Mol Endocrinol; 2001 Nov; 15(11):1941-52. PubMed ID: 11682625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
    Koschmieder S; Hofmann WK; Kunert J; Wagner S; Ballas K; Seipelt G; Hoelzer D; Ottmann OG; Kalina U
    Leukemia; 2001 Jun; 15(6):942-9. PubMed ID: 11417481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
    Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
    Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
    De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
    Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].
    Hu W; Zhang C; Zhang P; Wei D; Zhao Z; Cai M
    Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):25-7. PubMed ID: 12599420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.
    Rambaldi A; Attuati V; Bassan R; Neonato MG; Viero P; Battista R; Di Bona E; Rossi G; Pogliani E; Ruggeri M; Amaru R; Rivolta A; Giudici G; Biondi A; Barbui T
    Leuk Lymphoma; 1996 May; 21(5-6):457-66. PubMed ID: 9172811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
    Honma Y; Matsuo Y; Hayashi Y; Omura S
    Int J Cancer; 1995 Mar; 60(5):685-8. PubMed ID: 7860143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.